news and events
Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting Read more ›
episil® oral liquid is a unique local treatment of pain in the oral cavity resulting from inflammation and ulcers in the oral cavity. It has been demonstrated effective in treating e.g. oral mucositis, a severe and sometimes treatment limiting side effect of cancer chemotherapy or radiation. The product is administered as a lipid-based liquid that spreads on the mucosal surface where it transforms into a highly bioadhesive film, thereby protecting the sensitised and sore mucosa. episil® oral liquid is conveniently administered using small pocket sized pump device.
Camurus' FluidCrystal® injection depot delivers therapeutic levels of drug substance over extended periods - tunable from days to months - from a single injection! While traditional depot therapeutics comprise complicated microsphere technology, Camurus' depot offers a liquid solution that transforms into a controlled release liquid crystal gel matrix in situ on contact with minute quantities of aqueous fluid at site of injection.
CAM2038 is a new long-acting buprenorphine product for the stabilization and maintenance treatment of patients dependent on painkiller and illicit opioids. CAM2038 represents a new treatment concept for patients dependent on prescription pain killers and illicit opioids, and includes weekly (q1w) and monthly (q4w) buprenorphine injection products.
In addition to relieving the burdens of daily medication, CAM2038 products have been specifically designed for minimizing the risks of abuse, misdirection and pediatric exposure associated with presently marketed daily sublingual tablet and film products. Having successfully finalized Phase 1 and Phase 2 trials, Camurus is now continuing with Phase 3 development with the intent to start pivotal studies early 2015. Market approval submissions in US and EU are planned for 2016.
CAM2032 (Prosenze®) is a new convenient ready-to-use, long-acting leuprolide formulation in development for long-term treatment of prostate cancer. The product is presented as ready-to-use prefilled syringe containing a lipid-based leuprolide solution. It is administered as a low volume subcutaneous injection that rapidly transforms in situ to the FluidCrystal® controlled release matrix, providing consistent plasma levels over time. CAM2032 has been studies in one single dose Phase 2 trial in patients with prostate cancer and is currently being assessed in a second repeat dose Phase 2 trial versus an active comparator. A pivotal Phase 3 study is planned to start in the first half of 2015.